UBS Group
RARE icon

UBS Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

UBS Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,700
Closed -$379K – 8583
2015
Q2 		$379K Buy
+3,700
New +$287K ﹤0.01% 4350

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

UBS Group's RARE Position: Q2 2026 in Review

UBS Group reduced its Ultragenyx Pharmaceutical (RARE) stake by 21% in Q2 2026, selling an estimated $4.35M and leaving 657,699 shares worth $22M. The position accounts for ﹤0.01% of the portfolio, ranked #2584.

UBS Group first reported a position in RARE in Q4 2014 and has held it in 47 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • UBS Group held 657,699 shares of Ultragenyx Pharmaceutical worth $22M as of Q2 2026.
  • UBS Group sold 175,041 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $4.35M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2584 holding.
  • UBS Group first reported a position in Ultragenyx Pharmaceutical in Q4 2014 and has held it in 47 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.